23andMe Begins Phase 1 Trial for 23ME-01473 Antibody

23andMe Begins Phase 1 Trial for 23ME-01473 Antibody

23andMe Launches Phase 1 Trial for 23ME-01473 Antibody Targeting ULBP6

Overview

23andMe Holding Co. (Nasdaq: ME) has announced the initiation of a Phase 1 clinical trial for 23ME-01473 ('1473), targeting advanced solid tumors. This trial marks a significant milestone as the first participant receives dosing. The investigational antibody, ULBP6, targeted by '1473, was discovered through 23andMe's proprietary research platform, which utilizes the world's largest database of de-identified human genetic and phenotypic information. Remarkably, this marks the third drug target validated by 23andMe's research platform to enter clinical trials in less than four years.

Words from 23andMe

Jennifer Low, Head of Therapeutics Development at 23andMe, expressed enthusiasm, stating, “Entering the clinic with this exciting new dual-mechanism NK-cell activator reinforces the ability of the 23andMe Therapeutics team, and the potential of our research platform, to discover and develop new therapies informed by human genetics.”

Projected Mechanism of '1473

  • '1473 targets ULBP6 to enhance anti-tumor immunity via NK and T cells. ULBPs, found on cancer cells, bind to NKG2D receptors on NK and T cells. 
  • Cancer cells evade immune recognition by shedding ULBP ligands, acting as immunosuppressive decoys. 
  • '1473 aims to block this binding, potentially restoring immune cell recognition and killing of cancers. 
  • Additionally, '1473 is Fc-effector enhanced, offering another mechanism for NK cells to induce cancer cell death.

The identification of ULBP6 as a potential drug target was facilitated by 23andMe's immuno-oncology (I/O) genetic signature, utilizing genetic data to identify immune-related genes impacting cancer biology and risk.

Phase 1 Study

  • The Phase 1 '1473 study is a first-in-human, multi-center, open-label trial assessing safety and tolerability in individuals with locally advanced or metastatic solid malignancies progressing after standard therapy. 
  • This study will also evaluate '1473's pharmacokinetic and pharmacodynamic profile to establish the optimal dose and schedule for further clinical investigations.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!